Guidance
- In 2025, sales are anticipated to grow by a high single-digit percentage at CER (previously mid-to-high single-digit). Sanofi confirms the expectation of a strong business EPS rebound with growth at a low double-digit percentage at CER (before share buyback), now including all expenses from newly acquired businesses4
- Sanofi intends to complete its €5 billion share buyback program in 2025. 80.3% has been repurchased to date